Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc has demonstrated consistent annual revenue growth since the launch of its product Dextenza in July 2019, signaling robust market acceptance and potential for future sales expansion. The company's proprietary hydrogel platform technology offers innovative solutions to overcome the limitations of current eye-drop-based therapies, positioning it favorably within the growing anti-VEGF treatment market, which is projected to reach approximately $18 billion by 2028, with a CAGR of 8%-10%. Additionally, the anticipated readout of Axpaxli's SOL-1 trial in 1Q26 could further validate the product's potential and contribute to significant upside, reinforcing an optimistic outlook for the company's future performance.

Bears say

Ocular Therapeutix faces significant challenges due to a steep decline in sales, reported at a 68% year-over-year drop, driven by increased competition from biosimilars and newer treatment options such as Vabysmo and Eylea HD, resulting in substantial market share erosion. The company's proprietary hydrogel technology, while innovative, may not sufficiently address the treatment burden associated with anti-VEGF therapies, leading to poor patient compliance and worse real-world outcomes compared to clinical trials. Additionally, issues related to treatment interruptions and adverse events, such as intraocular inflammation, pose risks to the company's growth prospects and its ability to fund future pipeline programs.

Ocular Therapeutix (OCUL) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 20 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Sep 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.